Citadel Advisors’s AngioDynamics ANGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$190K Buy
16,700
+3,200
+24% +$34.7K ﹤0.01% 11465
2025
Q4
$173K Sell
13,500
-17,700
-57% -$218K ﹤0.01% 11165
2025
Q3
$349K Buy
31,200
+10,500
+51% +$101K ﹤0.01% 10013
2025
Q2
$205K Buy
20,700
+1,800
+10% +$17.6K ﹤0.01% 10630
2025
Q1
$177K Buy
18,900
+6,900
+58% +$72.5K ﹤0.01% 10620
2024
Q4
$110K Buy
12,000
+3,100
+35% +$22.8K ﹤0.01% 11344
2024
Q3
$69.2K Buy
8,900
+5,800
+187% +$41.9K ﹤0.01% 11574
2024
Q2
$18.8K Sell
3,100
-200
-6% -$1.23K ﹤0.01% 12699
2024
Q1
$19.4K Buy
3,300
+700
+27% +$4.16K ﹤0.01% 13037
2023
Q4
$20.4K Buy
2,600
+1,900
+271% +$13.2K ﹤0.01% 12604
2023
Q3
$5.12K Sell
700
-1,000
-59% -$8.32K ﹤0.01% 13419
2023
Q2
$17.7K Sell
1,700
-4,300
-72% -$41.4K ﹤0.01% 12839
2023
Q1
$62K Buy
6,000
+5,500
+1,100% +$70.4K ﹤0.01% 11882
2022
Q4
$6.88K Buy
+500
New +$6.96K ﹤0.01% 13874
2022
Q1
Sell
-7,800
Closed -$215K 13498
2021
Q4
$215K Sell
7,800
-1,100
-12% -$30.4K ﹤0.01% 11690
2021
Q3
$231K Buy
+8,900
New +$238K ﹤0.01% 11660
2021
Q2
Sell
-10,200
Closed -$239K 13606
2021
Q1
$239K Buy
+10,200
New +$206K ﹤0.01% 11336
2020
Q4
Sell
-11,400
Closed -$137K 10867
2020
Q3
$137K Buy
+11,400
New +$108K ﹤0.01% 9067
2019
Q2
Sell
-10,400
Closed -$238K 9119
2019
Q1
$238K Buy
+10,400
New +$226K ﹤0.01% 7946
2016
Q4
Sell
-12,500
Closed -$219K 7206
2016
Q3
$219K Buy
+12,500
New +$203K ﹤0.01% 6180

Other funds holding ANGO

Citadel Advisors's ANGO Position: Q1 2026 in Review

Citadel Advisors reduced its AngioDynamics (ANGO) stake by 5% in Q1 2026, selling an estimated $27.8K and leaving 48,322 shares worth $549K. The position accounts for ﹤0.01% of the portfolio, ranked #9069.

Citadel Advisors first reported a position in ANGO in Q1 2014 and has held it in 41 quarters since. The position peaked at $7.95M in Q4 2023. 147 funds tracked by Wall St. Rank hold ANGO as of Q1 2026.

  • Citadel Advisors held 48,322 shares of AngioDynamics worth $549K as of Q1 2026.
  • Citadel Advisors sold 2,561 AngioDynamics shares in Q1 2026, an estimated $27.8K.
  • AngioDynamics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9069 holding.
  • Citadel Advisors first reported a position in AngioDynamics in Q1 2014 and has held it in 41 quarters since.
  • Citadel Advisors's AngioDynamics position peaked at $7.95M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.